SarcopeniaNCT06166134
Radiological Evaluation of Sarcopenia in Patient Received Chemotherapy
An observational study of Sarcopenia, run by Assiut University.
Trial summary
Radiological evaluation of sarcopenia in patients receiving chemotherapy Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Sarcopenia
- How many people
- 72 participants
- Where
- No sites listed yet
- Study dates
- Jan 2024to Apr 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Comparison of muscle mass before and after chemotherapy by use of sonoelastography and computed tomography and comparison with normal volunteer
Who may be able to join
- all cancer patients receiving chemotherapy referred to radiodiagnosis department for routine examination Patients must be between 18 and
Who cannot join
- Previous or current history of any musculoskeletal or neurological disorder including strokes.
- Systemic atrophy affecting CNS ( Huntington disease ,hereditary ataxia ,spinal muscular disorder and related syndromes ,post polio syndrome )
- Central nervous system demyelinating disease ( Multiple sclerosis , acute disseminated demyelinated syndromes..
- Corticosteroids undertaken currently or for the past 3 years with doses >5mg/day.
Trial locations and contacts
No sites are listed yet.
About this study
Radiological evaluation of sarcopenia in patients receiving chemotherapy
Read the detailed description
Evaluation of muscle mass by using sonoelastography and computed tomography
- Conditions
- Sarcopenia
- Medical subject headings
- Sarcopenia
What is being measured
The primary outcome is the main question the study is designed to answer.
Radiological evaluation of sarcopenia in patients receiving chemotherapy
Using sonoelastography and computed tomography in evaluation of muscle mass in patients received chemotherapy by measurement of muscle thickness ,echogencity ,cross sectional area ,fasicle length,pennation angle, strain ratio,shear wave velocity
Measured: April 2025
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Dec 2023
- Study startJan 2024 (estimated)
- Primary completionApr 2025 (estimated)
- Study completionApr 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SarcopeniaStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 72 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Doaa Maher, Assiut University
- Investigators
- Lamiaa Refaat, Assisstant professor, Study director, Assiut university -south egypt cancer instituteOmar Mostafa, Assisstant professor, Study director, Assiut university -south egypt cancer institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06166134
- Sponsor's protocol ID
- Us and CT in sarcopenia
- Status last verified
- Dec 2023
- First submitted
- 2 Dec 2023
- Last updated
- 12 Dec 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Dec 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Radiological Evaluation of Sarcopenia in Patient Received Chemotherapy
- ClinicalTrials.gov ID
- NCT06166134
- Acronym / sponsor ID
- Us and CT in sarcopenia
- Conditions
- Sarcopenia
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 72 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- Jan 2024 (estimated)
- Primary completion
- Apr 2025 (estimated)
- Study completion
- Apr 2025 (estimated)
- First posted
- 12 Dec 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Radiological evaluation of sarcopenia in patients receiving chemotherapy
Detailed description
Evaluation of muscle mass by using sonoelastography and computed tomography
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Comparison of muscle mass before and after chemotherapy by use of sonoelastography and computed tomography and comparison with normal volunteer
Key inclusion criteria (1 listed)
- all cancer patients receiving chemotherapy referred to radiodiagnosis department for routine examination Patients must be between 18 and
Key exclusion criteria (4 listed)
- Previous or current history of any musculoskeletal or neurological disorder including strokes.
- Systemic atrophy affecting CNS ( Huntington disease ,hereditary ataxia ,spinal muscular disorder and related syndromes ,post polio syndrome )
- Central nervous system demyelinating disease ( Multiple sclerosis , acute disseminated demyelinated syndromes..
- Corticosteroids undertaken currently or for the past 3 years with doses >5mg/day.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Radiological evaluation of sarcopenia in patients receiving chemotherapy
Time frame: April 2025
Using sonoelastography and computed tomography in evaluation of muscle mass in patients received chemotherapy by measurement of muscle thickness ,echogencity ,cross sectional area ,fasicle length,pennation angle, strain ratio,shear wave velocity
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Dec 2023.
- Related InfoLink provided by the sponsor.
- Related InfoLink provided by the sponsor.
Related trials for Sarcopenia
Enrolling by invitation
Online Exercise Program for Transplant Patients: A Pilot Study
Kidney Transplantation, Physical Function
Not yet recruitingPhase 2
A Study of Bimagrumab in Participants With HFpEF
Heart Failure, Diastolic, Diastolic Heart Failure
Not yet recruiting
The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.
COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly
Not yet recruitingPhase 2
MF-300 for Treatment of Age-Related Sarcopenia
Sarcopenia in Elderly
Not yet recruitingObservational study
Validation of Uzbek SARC-F and IPAQ-SF Questionnaires in Adults With and Without Hypothyroidism
Hypothyroidism, Psychometrics
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lamiaa Refaat, Assisstant professor study director
Assiut university -south egypt cancer institute
Omar Mostafa, Assisstant professor study director
Assiut university -south egypt cancer institute
Questions about this trial
What is this clinical trial studying?
An observational study of Sarcopenia, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 12 Dec 2023. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Doaa Maher ebied Maher, Resident (01050147500, dm953407@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Radiological evaluation of sarcopenia in patients receiving chemotherapy (time frame: April 2025). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Dec 2023; AzTrials last refreshed its copy on 7 Nov 2026.